Celltrion has obtained the Food and Drug Administration’s clearance for a new presentation of Steqeyma (ustekinumab-stba), a biosimilar to Stelara (ustekinumab), in a 45mg/0.5ml solution in a ...
Please provide your email address to receive an email when new articles are posted on . The FDA approved Steqeyma as the seventh Stelara biosimilar with an expected launch date of February 2025.
Sandoz has received the Food and Drug Administration’s permission for Pyzchiva (ustekinumab-ttwe), 45 mg/0.5 ml and 90 mg/ml pre-filled syringes for subcutaneous injection and 130 mg/26 ml (5 mg/ml) ...
Yesintek, a Stelara biosimilar, received FDA approval for IBD, plaque psoriasis, and psoriatic arthritis, with a launch expected in late 2025. Clinical trials confirmed Yesintek's equivalence to ...
Fresenius Kabi, an Operating Company of Fresenius, and a leading provider of essential medicines and medical technologies, announced today it has introduced a new presentation of Otulfi ® (ustekinumab ...
Teva Pharmaceuticals and Alvotech have announced that the US Food and Drug Administration (FDA) has approved the Selarsdi (ustekinumab-aekn) injection as interchangeable with reference biologic ...
PARSIPPANY, N.J. and REYKJAVIK, Iceland, May 05, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (TEVA), and Alvotech (ALVO) today announced that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results